Search results
Showing 931 to 945 of 1214 results for pain
This guideline covers preventing and treating surgical site infections in adults, young people and children who are having a surgical procedure involving a cut through the skin. It focuses on methods used before, during and after surgery to minimise the risk of infection.
Urinary tract infection (lower): antimicrobial prescribing (NG109)
This guideline sets out an antimicrobial prescribing strategy for lower urinary tract infection (also called cystitis) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Discontinued Reference number: GID-TAG367
End of life care for infants, children and young people (QS160)
This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS160Show all sections
Sections for QS160
- Quality statements
- Quality statement 1: Advance care plan
- Quality statement 2: Named medical specialist
- Quality statement 3: Emotional and psychological support
- Quality statement 4: Specialist paediatric palliative care team
- Quality statement 5: Support for grief and loss for parents or carers
- Quality statement 6: Care at home
- About this quality standard
This quality standard covers assessing and managing motor neurone disease, including care, support and planning after diagnosis. It describes high-quality care in priority areas for improvement.
View quality statements for QS126Show all sections
Sections for QS126
- Quality statements
- Quality statement 1: Information and support at diagnosis
- Quality statement 2: Respiratory assessment and non-invasive ventilation
- Quality statement 3: Provision of equipment and adaptions based on multidisciplinary team assessment
- Quality statement 4: Continuity of care
- Quality statement 5: Planning for end of life care
- About this quality standard
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for HTG171Show all sections
Sections for HTG171
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable.
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.